CONBERCEPT IN PATIENTS WITH TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE SETTING IN CHINA.
In this study, we aimed to evaluate the efficacy and safety of intravitreal conbercept in patients with treatment-naive neovascular age-related macular degeneration in real-life setting. Three consecutive intravitreal injections of conbercept following a pro re nata protocol. The main outcomes were the changes of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity and central retinal thickness between the baseline and the 12th month. Mean best-corrected visual acuity was improved from 39.39 ± 24.91 letters at the baseline to 44.26 ± 22.89 letters at the final follow-up (P < 0.001). At the 12th month, the proportion of optimal response was 43.48% compared with 36.96% of poor response and 19.56% of nonresponse. A mean central retinal thickness of 480.94 ± 178.47 μm at the baseline was significantly reduced to 366.33 ± 173.52 μm at the 12th month. Patients received a median of 5.32 intravitreal injections. At the 12th month, the mean change in best-corrected visual acuity of eyes with intraretinal cystoid fluid from the baseline was markedly lower than that of eyes without intraretinal cystoid fluid. No adverse events were attributed to conbercept. With 12-month follow-up, conbercept was proved to be an effective and safety treatment for patients with treatment-naive neovascular age-related macular degeneration in real-life setting.